These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31217437)

  • 41. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
    Hosoi A; Takeda K; Nagaoka K; Iino T; Matsushita H; Ueha S; Aoki S; Matsushima K; Kubo M; Morikawa T; Kitaura K; Suzuki R; Kakimi K
    Sci Rep; 2018 Jan; 8(1):1058. PubMed ID: 29348598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
    McGray AJ; Hallett R; Bernard D; Swift SL; Zhu Z; Teoderascu F; Vanseggelen H; Hassell JA; Hurwitz AA; Wan Y; Bramson JL
    Mol Ther; 2014 Jan; 22(1):206-18. PubMed ID: 24196579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
    Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
    Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
    Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
    Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.
    Sultan H; Kumai T; Fesenkova VI; Fan AE; Wu J; Cho HI; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2018 May; 6(5):617-627. PubMed ID: 29483127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preface: More than two decades of modern tumor immunology.
    Galluzzi L; Rudqvist NP
    Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of neoantigens in response to immune checkpoint blockade.
    Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
    Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
    Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
    Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoantigens in the immuno-oncology space.
    Arlen PM
    Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
    [No Abstract]   [Full Text] [Related]  

  • 53. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
    Sahin U; Oehm P; Derhovanessian E; Jabulowsky RA; Vormehr M; Gold M; Maurus D; Schwarck-Kokarakis D; Kuhn AN; Omokoko T; Kranz LM; Diken M; Kreiter S; Haas H; Attig S; Rae R; Cuk K; Kemmer-Brück A; Breitkreuz A; Tolliver C; Caspar J; Quinkhardt J; Hebich L; Stein M; Hohberger A; Vogler I; Liebig I; Renken S; Sikorski J; Leierer M; Müller V; Mitzel-Rink H; Miederer M; Huber C; Grabbe S; Utikal J; Pinter A; Kaufmann R; Hassel JC; Loquai C; Türeci Ö
    Nature; 2020 Sep; 585(7823):107-112. PubMed ID: 32728218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
    Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
    Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
    [No Abstract]   [Full Text] [Related]  

  • 55. Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.
    Cecil D; Park KH; Curtis B; Corulli L; Disis MN
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens.
    Grimaldi A; Cammarata I; Martire C; Focaccetti C; Piconese S; Buccilli M; Mancone C; Buzzacchino F; Berrios JRG; D'Alessandris N; Tomao S; Giangaspero F; Paroli M; Caccavale R; Spinelli GP; Girelli G; Peruzzi G; Nisticò P; Spada S; Panetta M; Letizia Cecere F; Visca P; Facciolo F; Longo F; Barnaba V
    Commun Biol; 2020 Feb; 3(1):85. PubMed ID: 32099064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
    Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
    Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preface: More than two decades of modern tumor immunology.
    Galluzzi L; Rudqvist NP
    Methods Enzymol; 2020; 632():xxiii-xlii. PubMed ID: 32000917
    [No Abstract]   [Full Text] [Related]  

  • 60. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
    Li TJ; Wang WQ; Yu XJ; Liu L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.